Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Independent evaluation of the Access to Medicine Index (summary)

Publication date: 9 März 2016 | Report language: EN

Technopolis Group has conducted an evaluation of the Access to Medicine Index, for which an executive summary was published. The evaluation showed that, by providing the pharmaceutical industry with a tool for learning and discussion, the Access to Medicine Index has proven a catalyst for accelerating current access-to-medicine activities and has inspired the development of new activities.

The Access to Medicine Index is published every two years by the Access to Medicine Foundation to stimulate and guide the world’s 20 largest pharmaceutical companies to do more in providing access to medicine to people in low- and middle-income countries.

For this study, Technopolis Group developed a comprehensive Theory of Change. Through many interviews with representatives from indexed and non-indexed companies, and external stakeholders, Technopolis Group was able to identify different pathways of influence and assess their absolute and relative effectiveness.

Technopolis Group has provided the Foundation with a number of recommendations for the future of the Index. These focus on ways to consolidate the achievements of the Foundation to date and further increase the impact of the current activities. Suggestions are also provided for areas in which to expand the activity portfolio.

For more information: A detailed press release is available on the website of the Access to Medicine Index.